IXICO (LON:IXI) Stock Passes Above 50-Day Moving Average – Should You Sell?

IXICO plc (LON:IXI) shares passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 11.72 ($0.15) and traded as high as GBX 12 ($0.15). IXICO shares last traded at GBX 11.50 ($0.14), with a volume of 5,195 shares changing hands.

IXICO Trading Down 3.7 %

The company has a debt-to-equity ratio of 3.22, a quick ratio of 4.90 and a current ratio of 3.64. The company’s 50-day moving average price is GBX 11.83 and its 200-day moving average price is GBX 9.73. The firm has a market capitalization of £5.59 million, a PE ratio of -288.90, a PEG ratio of -0.38 and a beta of 0.86.

IXICO (LON:IXI) last announced its quarterly earnings results on Wednesday, December 4th. The company reported GBX (4.14) (($0.05)) earnings per share (EPS) for the quarter. IXICO had a negative return on equity of 16.99% and a negative net margin of 31.10%. On average, sell-side analysts expect that IXICO plc will post -289.3584879 earnings per share for the current year.

Insider Activity at IXICO

In related news, insider Grant Nash purchased 260,000 shares of IXICO stock in a transaction that occurred on Wednesday, December 4th. The stock was purchased at an average cost of GBX 12 ($0.15) per share, with a total value of £31,200 ($38,956.17). 30.28% of the stock is currently owned by corporate insiders.

About IXICO

IXICO is a fast growing and profitable medical data analytics company, providing data management and advanced analytics to the pharmaceutical clinical trials market. Established in 2004 and listed as a public company in October 2013, IXICO has firmly established itself as a trusted partner to the global pharmaceutical industry developing new therapies for neurological conditions such as Alzheimer’s, Parkinson’s and Huntington’s disease.

Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.